Clinical Factors Associated with Carotid Plaque and Intima-Medial Thickness in HIV-Infected Patients

Su Jin Jeong; Hye Won Kim; Nam Su Ku; Sang Hoon Han; Chang Oh Kim; Jun Yong Choi; Young Goo Song; June Myung Kim

doi:10.3349/ymj.2013.54.4.990

Journal List > Yonsei Med J > v.54(4) > 1031320

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jeong, Kim, Ku, Han, Kim, Choi, Song, and Kim: Clinical Factors Associated with Carotid Plaque and Intima-Medial Thickness in HIV-Infected Patients

Original Article

Infectious Disease

Yonsei Medical Journal 2013; 54(4): 990-998.

Published online: 14 May 2013

DOI: https://doi.org/10.3349/ymj.2013.54.4.990

Clinical Factors Associated with Carotid Plaque and Intima-Medial Thickness in HIV-Infected Patients

Su Jin Jeong, Hye Won Kim, Nam Su Ku, Sang Hoon Han, Chang Oh Kim, Jun Yong Choi, Young Goo Song, June Myung Kim

Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author: Dr. Sang Hoon Han, Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-2228-1991, Fax: 82-2-393-6884 shhan74@yuhs.ac

Received 27 July 2012 Revised 15 October 2012 Accepted 22 October 2012

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

HIV-infected patients are at increased risk for cardiovascular disease, which may be mediated in part by inflammation. This study aimed to evaluate the risk factors of carotid plaque, and clinical factors associated with carotid atherosclerosis measured by carotid intima-medial thickness (cIMT) in HIV patients.

Materials and Methods

Clinical and cardiometabolic factors as well as cIMT were prospectively measured in 145 HIV-infected participants who had received combined antiretroviral therapy for ≥6 months. The mean value of the bilateral average cIMT level was used as Mean-IMT in the analysis, and the greatest value among the measured cIMT levels was used as Max-IMT.

Results

Among 145 patients, 34 (23.4%) had carotid plaque. Multivariate logistic regression analysis revealed three independent risk factors of carotid plaque: old age [odds ratio (OR) 6.16, 95% confidence interval (CI) 1.09-34.88; p=0.040], hypertension (OR 12.62, 95% CI 1.72-92.49; p=0.013) and higher low-density lipoprotein cholesterol (LDL-C) (OR 1.08, 95% CI 1.01-1.16; p=0.039). Levels of estimated glomerular filtration rate were inversely associated with Mean-IMT (r=-0.379, p<0.001) and Max-IMT (r=-0.389, p<0.001). Stepwise multivariate regression analyses revealed that age, total cholesterol and fasting glucose were positively correlated with cIMT, independent of other risk factors.

Conclusion

The presence of hypertension, old age and a higher level of LDL-C were independent risk factors of carotid plaque among HIV-infected subjects.

Keywords: Carotid plaque, carotid artery intima-media thickness, atherosclerosis, combined antiretroviral therapy, HIV infection

INTRODUCTION

Combined antiretroviral therapy (cART) plays a critical role in suppressing viral titers and increasing CD4+ T lymphocyte counts, which translate to significantly reduced morbidity and mortality in HIV-infected individuals.1,2 However, it now appears clear that both HIV infection itself and cART are associated with a higher risk of stroke and metabolic disorders.3,4 In a cross-sectional study of 292 subjects, a CD4+ T-cell count less than 100 cells/mm³ was associated with a higher densirisk of metabolic syndrome.5 In parallel, metabolic complications were frequently observed after a few years of cART initiation.6 Many morphologic and metabolic changes correspond to metabolic syndrome criteria, according to the Adult Treatment Panel III (ATPIII) definition.7 These metabolic complications have been shown to be with an increased lifespan in HIV patients on cART, and naturally raise the question of whether HIV patients are at a higher risk for cardiovascular morbidity.8 Therefore, early detection of atherosclerosis may be necessary to prevent cardiovascular disease (CVD) in HIV-infected patients receiving cART.

Atherosclerosis is commonly observed in the carotid and coronary arteries.9 Measurement of carotid intima-media thickness (cIMT) and atherogenic plaque using ultrasound (US) is a noninvasive, sensitive and reproducible method for identifying and quantifying subclinical vascular atherosclerosis and for evaluating the risk of CVD.10 It is well known that cIMT level is a surrogate marker of atherosclerosis,11 and is significantly associated with risks for myocardial infarction, stroke and coronary heart disease in individuals without symptomatic CVD.12,13 Carotid plaque has also been shown to be associated with cardiovascular events in healthy populations, with a prognostic power similar to or better than that of cIMT.14-16 In addition, pathological carotid US findings, including the existence of plaques and/or a cIMT level of more than 0.9 mm, exhibited a highly significant direct association with all cardiovascular risk predictors including estimated Framingham risk score in cART-naïve HIV patients.17,18

Several previous studies have revealed that a decrease in estimated glomerular filtration rate (eGFR) is one risk factor for CVD19 and is correlated with cardiovascular mortality and morbidity in both high-risk groups20,21 and the general population.22

To the best of our knowledge, studies have yet to investigate risk factors of carotid plaque and subclinical atherosclerosis according to cIMT level in HIV-infected Asians receiving cART. In addition, there is little data on the clinical characteristics and associated factors of subclinical carotid atherosclerosis including eGFR among HIV-infected subjects in the Asia-Pacific region. The objective of this study was to evaluate the risk factors of asymptomatic carotid plaque and the associations between cardiometabolic factors and carotid atherosclerosis as measured by cIMT in HIV-infected Asians and to discern whether eGFR level is associated with cIMT or the existence of plaque.

MATERIALS AND METHODS

Study population and design

HIV-infected Koreans, who had continuously received cART comprising more than three antiretroviral drugs for at least six months with good clinical compliance to regular trimonthly visits at a university-affiliated tertiary care referral hospital (Seoul, Republic of Korea), were requested to participate in the present study. We prospectively enrolled a total of 145 HIV-infected patients, excluding participants with a medication history of anti-platelet agents or statins that can affect cIMT level and plaque. The study protocol was approved by the Institutional Review Board of the Clinical Research Institute of Severance Hospital. Written informed consent was obtained from each participant.

Carotid IMT measurement

Carotid US was performed by a single specialist to determine the extent of subclinical carotid atherosclerosis. Scanning of the extracranial common carotid artery, carotid bulb, and internal carotid artery in the neck was performed bilaterally from three different longitudinal and transverse projections.23 The average distance between the inner echogenic line representing the luminal-intimal interface and the outer echogenic line representing the media-adventitia interface was calculated by automatic IMT measurement software (Intimascope; Media Cross, Tokyo, Japan).23,24 The mean value of the bilateral average cIMT level was used as Mean-IMT in the analysis, and the greatest value among the measured cIMT levels was used as Max-IMT. For carotid US, a high-resolution real-time B-mode US with a 10-MHz linear probe (LOGIQ 7; GE Medical Systems, Milwaukee, WI, USA) was used. Carotid plaque was defined as the presence of focal wall thickening that was at least 50% greater than that of the surrounding vessel wall, or as a focal region with a cIMT greater than 1.5 mm that protruded into the lumen and was distinct from the adjacent boundary.25

Body composition measurement and collection of laboratory and clinical data

Height, body weight, waist/hip circumference, and systolic and diastolic blood pressure (BP) were directly measured on the day of carotid US evaluation in all participants. Body mass index (BMI) and waist-hip ratio (WHR) were calculated. Blood samples were obtained after a 12 h overnight fast. Circulating levels of total cholesterol (T-C), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), fasting insulin, and fasting glucose were analyzed using an enzymatic colorimetric assay and lipoprotein electrophoresis (Hitachi, Tokyo, Japan). Homeostasis model assessment of insulin resistance as a marker for insulin resistance (IR) was calculated according to the following formula: [fasting glucose (mmol/L)×fasting insulin (µIU/mL)/22.5].26 CD4+ T lymphocyte count was measured by flow cytometry (Beckman Coulter, Fullerton, CA, USA), and plasma HIV-RNA viral load (VL) was obtained by Roche diagnostics (COBAS AMPLICOR HIV-1 MONITOR, version 2.42; Roche, Basel, Switzerland) with a lower detection limit of 40 copies per milliliter.

Kidney function was assessed through eGFR, which was calculated using the Modification of Diet in Renal Disease formula as follows27: 186.3×(serum creatinine^-1.154)×(age^-0.203)×(0.742 if female), with the serum creatinine concentration expressed as mg/dL. Clinical information including duration of known HIV infection and total duration of cART as well as all exposed antiretroviral drugs were collected. Based on the ATPIII criteria,7 metabolic syndrome was defined as the presence of three or more or the following components: 1) waist circumference >88 cm in women or >102 cm in men; 2) systolic BP ≥130 mm Hg or diastolic ≥85 mm Hg or use of antihypertensive medications; 3) TG ≥150 mg/dL or use of lipid lowering medications (niacin, fenofibrate, and gemfibrozil); 4) fasting blood glucose ≥100 mg/dL, physician diagnosed diabetes or use of diabetic medications; 5) HDL-C <50 mg/dL in women or <40 mg/dL in men. Hypertension was defined as the second component mentioned above.

Statistical analysis

All variables are expressed as the mean±standard deviation or number (percent), unless otherwise indicated. Statistical significance was set at p<0.05. Categorical variables were compared by χ² analysis, and continuous variables with normal distributions were compared by Student's t test. We analyzed the continuous variables for normal distribution through the one-sample Kolmogorov-Smirnov test. Variables with p<0.05 in bivariate analysis were included in the logistic regression model for multivariate analysis to estimate the odds ratio (OR) of the risk of carotid plaque, along with the 95% confidence interval (CI). Single linear univariate correlations (Pearson's correlation coefficients) and stepwise multivariate regression analyses were performed to evaluate the relationships between the value of cIMT or eGFR and other variables. The predictive power of cIMT to discriminate patients who had carotid plaque from those who did not was assessed by calculating the area under the receiver operating characteristic (ROC) curve (AUC). The AUC ranged from 0.5 to 1.0, and the greater the AUC was, the better the variables were. The optimal cutoff values of cIMT were selected to maximize the sum of the sensitivity and specificity derived from the ROC curves and the AUC analysis (Youden index). All statistical analyses were performed using SPSS 12.0 software (SPSS Inc., Chicago, IL, USA).

RESULTS

Thirty-four (23.4%) of the 145 patients had carotid atherogenic plaque. The mean age of the patients was 40.9±10.8 years, and 139 patients were male. The mean duration of known HIV infection was 53.0±44.7 months, and the mean total duration of cART was 36.7±29.5 months. The mean values of CD4+ T lymphocyte count and log₁₀[plasma HIV-RNA VL] at the time of cIMT measurement were 349.1±176.2 cells/µL and 1.79±0.66 copies/mm³, respectively (Table 1).

Patients with carotid plaque were significantly older (49.0±10.4 yrs vs. 38.4±9.7 yrs, p<0.001) and had a higher prevalence of hypertension (38.7% vs. 7.3%, p<0.001), cerebro-vascular attack (CVA) (12.9% vs. 0.0%, p=0.002), diabetes mellitus (12.9% vs. 1.8%, p=0.021) and metabolic syndrome (41.2% vs. 23.4%, p=0.043), compared to patients without plaque. WHR was significantly higher in patients with carotid plaque than in those without (0.88±0.05 vs. 0.85±0.04, p=0.001) (Table 1).

Among the serum lipid profiles, glucose, and IR parameters, T-C (181.6±36.7 mg/dL vs. 168.8±29.6 mg/dL, p=0.039), LDL-C (87.2±24.4 mg/dL vs. 74.9±25.3 mg/dL, p=0.033), glucose (106.9±25.6 mg/dL vs. 97.7±10.8 mg/dL, p=0.003), and fasting glucose-insulin ratio (13.09±13.87 vs. 8.41±7.63, p=0.023) were significantly higher in patients with carotid plaque than in those without. In addition, the carotid plaque group had a higher cIMT level (Mean-IMT; 0.68±0.17 mm vs. 0.56±0.09 mm, p<0.001 and Max-IMT; 0.82±0.22 mm vs. 0.66±0.11 mm, p<0.001) and lower eGFR (90.58±19.14 mL/min per 1.73 m² vs. 97.22±14.59 mL/min per 1.73 m², p=0.033) (Table 1). However, variables associated with HIV infection and cART were not significantly different between the groups (Table 2).

In the multivariate logistic regression model to identify risk factors for carotid artery plaque in HIV-infected patients receiving cART, older age (older than 40 years, OR 6.16, 95% CI 1.09-34.88, p=0.040), hypertension (OR 12.62, 95% CI 1.72-92.49, p=0.013), and higher LDL-C level (OR 1.08, 95% CI 1.01-1.16, p=0.039) were identified (Table 3).

The ability of Mean-IMT and Max-IMT to predict carotid artery plaque was further examined by ROC curve analyses. The AUCs for Mean-IMT and Max-IMT were 0.74 (95% CI 0.65-0.84, p<0.001) and 0.76 (95% CI 0.67-0.85, p<0.001), respectively. The cut-off level for the greatest sensitivity and specificity for Mean-IMT was 0.62 mm (sensitivity=0.59 and specificity=0.82), and that for Max-IMT was 0.71 mm (sensitivity=0.61 and specificity=0.76) (Fig. 1).

The levels of eGFR were inversely associated with Mean-IMT (r=-0.379, p<0.001) and Max-IMT (r=-0.389, p<0.001). Correlations between cIMT and clinical and metabolic variables are shown in Table 4. Max-IMT and Mean-IMT had a significantly positive correlation with age (r=0.591, p<0.001, and r=0.589, p<0.001, respectively), BMI (r=0.189, p<0.024, and r=0.168, p<0.044 respectively), WHR (r=0.372, p<0.001, and r=0.353, p<0.001, respectively), T-C (r=0.282, p=0.001, and r=0.242, p=0.003, respectively), LDL-C (r=0.258, p=0.006, and r=0.208, p=0.026, respectively), and fasting glucose (r=0.292, p<0.001, and r=0.294, p<0.001). In addition, the total duration of cART was significantly positively associated with Max-IMT and Mean-IMT (r=0.175, p=0.036, and r=0.177, p=0.034, respectively) in univariate analysis. In the multiple stepwise regression analyses, age (p<0.001 and p<0.001, respectively), T-C (p=0.003 and p=0.031, respectively), and fasting glucose (p=0.012 and p=0.009, respectively) remained significant clinical factors independently associated with Max-IMT and Mean-IMT (adjusted R²=0.384 and 0.345, respectively) (Table 4).

DISCUSSION

The present study revealed that older age (≥40 years), hypertension and higher LDL-C level are the independent clinical factors associated with the existence of carotid plaque in HIV-infected Koreans receiving cART. In addition, we confirmed that Max-IMT and Mean-IMT are significantly associated with the existence of carotid plaque and found that cIMT is correlated with traditional CVD risk factors in HIV-infected Koreans.

According to our multivariate analysis, the presence of documented hypertension and a 1 mg/dL increase in LDL-C were associated with 12.62 and 1.08 times higher risk of carotid plaque, respectively. In addition, older patients with HIV demonstrated a greater incidence of carotid plaque (especially those over 40). It is generally well accepted that hypertension and dyslipidemia promote atherosclerosis and consequently increase IMT in non-HIV-infected individuals.28 Prospective studies of large populations have reported a correlation between circulating concentration of total cholesterol and LDL-C with IMT in both non-HIV-infected Caucasian28 and Eskimos.29 Also, older age is known to be a major risk factor for the development of CVD.30 Endothelium-dependent dilation of vessels becomes impaired with age,31,32 and is thought to contribute to the age-associated increase in CVD risk.30 In our study, we observed similar associations between hypertension, LDL-C, age and carotid plaque in HIV-infected patients receiving cART.

The results of our study reveal that the presence of subclinical carotid plaque is a frequent occurrence among HIV-infected patient receiving cART (23.4%). Our present observation, however, could be limited by the absence of age-matched HIV non-infected controls. Nevertheless, this high prevalence is in line with other previous observations,33,34 and only 6.7% of subclinical carotid lesions have been observed in an age-matched control group of 104 HIV-negative subjects. Furthermore, 20.9% of subclinical carotid lesions have been reported in HIV-infected patients naïve to cART.18

Although the wide performance of cART has prolonged the life expectancy of individuals infected with HIV,35 the accelerated onset of CVD has emerged as a concerning complication of chronic HIV infection and long-term use of cART.36 Moreover, there is increasing evidence supporting the initiation of cART in asymptomatic HIV-infected patients and a CD4+ T lymphocyte count >500 cells/mm³.37 It is, therefore, increasingly more relevant to stratify patients for CVD risk when cART is being initiated or when treatment regimens are being adjusted.38 Arterial stiffness, a marker of CVD and an independent predictor of its corresponding risk, is associated with impaired endothelial function.39 HIV may affect the vasculature directly via endothelial damage,40 and the virus-mediated inhibition of cholesterol efflux from macrophages with consequent reduced HDL-C levels,41 which promotes arterial stiffness and contributes to atherogenesis.42 Furthermore, HIV treatment, especially protease inhibitors may accelerate atherosclerosis especially due to metabolic side effects including dyslipidemia and IR.43,44 However, we found that subclinical carotid atherosclerosis was not associated with duration of HIV infection or cART regimen. Any association of HIV with atherosclerosis remains vague because of discrepant findings among these studies and the likelihood of bias affecting some study results. cART induces not only metabolic effects including dyslipidemia, but also antimetabolic effects such as recovery from immunosuppression and HIV VL suppression. These effects might explain our results that HIV and cART were not associated with carotid atherosclerosis.

A non-dipping BP profile of abnormal diurnal BP rhythm and a reduced nocturnal BP fall was highly prevalent in cART-naïve HIV patients. And this pattern is currently regarded as a risk factor in its own right for cardiovascular events and target organ damage.45 It has been suggested that the mechanism of a non-dipping pattern involves the association of non-dipping with salt-sensitive forms of hypertension, renal function impairment and mineralocorticoid-induced forms of hypertension, but this is not yet clear.46 In our study, we could not check diurnal BP rhythm, and a BP pattern in HIV-infected patients receiving cART is warranted.

In the present study, we found that the cut-off levels of Max-IMT and Mean-IMT were 0.71 mm and 0.62 mm, respectively, for predicting the presence of carotid plaque. For the same BMI or waist circumference, Asians have a higher prevalence of hypertension and, a higher percentage of body fat, diabetes and dyslipidemia as well as clustering of these risk factors, compared with Caucasians.47-50 Although there are now ethnic-specified definitions for obesity,47 these cutoff points do not take into consideration the possible interethnic differences in body build and body fat distribution among different Asian ethnic groups.49,50 Considering interethnic differences of metabolic complications, the results of our study suggest that the cut-off values of Max-IMT and Mean-IMT might be useful for early detection of carotid atherosclerosis in Asian patients with HIV.

We also observed significant correlations between cIMT and other classical CVD risk factors such as age, T-C and fasting glucose. Increasing cIMT is known to be closely related with systemic atherosclerosis, including CAD and CVA. Many prospective studies have shown that the development of cIMT progresses to cardiovascular events.11,51,52 Therefore, elevated T-C and fasting glucose may account for early atherosclerosis in HIV-infected patients.

There are several limitations to our study. The study design was cross-sectional, which means that we cannot infer causality. Future prospective studies are required to evaluate the predictive power of risk factors on the future risk of CVD and all-cause mortality in a large multiethnic cohort. Additional limitations include the lack of an HIV-seronegative control group for comparison.

In spite of these limitations, this study has clinical significance since it is the first report to evaluate the relationships between carotid atherosclerosis and metabolic risk factors in Asian patients with HIV. In conclusion, we demonstrated that the presence of hypertension, high LDL-C and old age are independent clinical factors of carotid plaque among HIV-infected Koreans. Future studies on the process of atherosclerosis in HIV-infected patients receiving cART are needed, including direct comparison between multiethnic HIV-infected patients and non-HIV-infected subjects.

Figures and Tables

Fig. 1

ROC curves for Max-IMT and Mean-IMT for the prediction of carotid artery plaque. The area under the ROC curves for Mean-IMT and Max-IMT were 0.74 (95% CI 0.65-0.84, p<0.001) and 0.76 (95% CI 0.67-0.85, p<0.001), respectively. CI, confidence interval; IMT, intima-media thickness; ROC, receiver operating characteristic.

Table 1

Characteristics of all Patients and Comparison of Clinical and Laboratory Parameters between the Carotid Plaque and Non-Plaque Group

BMI, body mass index; BP, blood pressure; CVA, cerebro-vascular accident; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; GI ratio, glucose-insulin ratio; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; IMT, intima-media thickness; LDL-C, low-density lipoprotein cholesterol; T-C, total cholesterol; TG, triglycerides; WHR, waist-hip-ratio.

Data are expressed as mean±standard deviation or number (percent).

^*Fisher's Exact Test.

Table 2

Comparison of Variables of HIV Infection and cART between the Carotid Plaque and Non-Plaque Group

cART, combined antiretroviral therapy; NNRTI, nonnucleoside analogue reverse transcriptase inhibitor; NRTI, nucleoside analogue reverse transcriptase inhibitor; PI, protease inhibitor; US, using ultrasound.

Data are expressed as mean±standard deviation or number (percent).

^*These variables indicate continuous exposure history of PIs or NNRTIs or NRTI for more than six months before carotid US measurement.

Table 3

Multivariate Logistic Regression Model to Identify Clinical Factors Indicating the Existence of Carotid Artery Plaque in HIV-Infected Patients Receiving cART

cART, combined antiretroviral therapy; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; CI, confidence interval.

Table 4

Correlations between Max-IMT/Mean-IMT and Clinical and Metabolic Variables

BMI, body mass index; BP, blood pressure; cART, combined active antiretroviral therapy; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; IMT, intima-media thickness; LDL-C, low-density lipoprotein cholesterol; T-C, total cholesterol; TG, triglycerides; WHR, waist-hip-ratio.

β indicates regression coefficients.

^*Univariate coefficients.

^†Stepwise multivariate regression analysis.

Notes

The authors have no financial conflicts of interest.

References

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338:853–860.

2. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002; 16:1663–1671.

3. Mochan A, Modi M, Modi G. Stroke in black South African HIV-positive patients: a prospective analysis. Stroke. 2003; 34:10–15.

4. Brannagan TH 3rd. Retroviral-associated vasculitis of the nervous system. Neurol Clin. 1997; 15:927–944.

5. Bonfanti P, De Socio GL, Marconi P, Franzetti M, Martinelli C, Vichi F, et al. Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study. Curr HIV Res. 2010; 8:165–171.

6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999; 353:2093–2099.

7. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640–1645.

8. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010; 24:1228–1230.

9. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998; 128:262–269.

10. Stein JH, Korcarz CE, Post WS. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: summary and discussion of the American Society of Echocardiography consensus statement. Prev Cardiol. 2009; 12:34–38.

11. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999; 340:14–22.

12. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997; 146:483–494.

13. Lorenz MW, von Kegler S, Steinmetz H, Markus HS, Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke. 2006; 37:87–92.

14. Kitamura A, Iso H, Imano H, Ohira T, Okada T, Sato S, et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men. Stroke. 2004; 35:2788–2794.

15. Rosvall M, Janzon L, Berglund G, Engström G, Hedblad B. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med. 2005; 257:430–437.

16. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation. 2004; 109:1089–1094.

17. De Socio GV, Martinelli C, Ricci E, Orofino G, Valsecchi L, Vitiello P, et al. Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES study. Int J STD AIDS. 2010; 21:267–272.

18. Maggi P, Quirino T, Ricci E, De Socio GV, Gadaleta A, Ingrassia F, et al. Cardiovascular risk assessment in antiretroviral-naïve HIV patients. AIDS Patient Care STDS. 2009; 23:809–813.

19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39:2 Suppl 1. S1–S266.

20. De Leeuw PW, Thijs L, Birkenhäger WH, Voyaki SM, Efstratopoulos AD, Fagard RH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol. 2002; 13:2213–2222.

21. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD. Heart and Estrogen/progestin Replacement Study (HERS) Investigators. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001; 38:705–711.

22. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13:745–753.

23. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986; 74:1399–1406.

24. Yanase T, Nasu S, Mukuta Y, Shimizu Y, Nishihara T, Okabe T, et al. Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens. 2006; 19:1206–1212.

25. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007; 23:75–80.

26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–419.

27. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999; 130:461–470.

28. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007; 115:459–467.

29. Masulli M, Patti L, Riccardi G, Vaccaro O, Annuzzi G, Ebbesson SO, et al. Relation among lipoprotein subfractions and carotid atherosclerosis in Alaskan Eskimos (from the GOCADAN Study). Am J Cardiol. 2009; 104:1516–1521.

30. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation. 2003; 107:346–354.

31. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994; 24:471–476.

32. Eskurza I, Kahn ZD, Seals DR. Xanthine oxidase does not contribute to impaired peripheral conduit artery endothelium-dependent dilatation with ageing. J Physiol. 2006; 571(Pt 3):661–668.

33. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000; 14:F123–F128.

34. Maggi P, Lillo A, Perilli F, Maserati R, Chirianni A. PREVALEAT Group. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS. 2004; 18:1023–1028.

35. Couzigou C, Semaille C, Le Strat Y, Pinget R, Pillonel J, Lot F, et al. Differential improvement in survival among patients with AIDS after the introduction of HAART. AIDS Care. 2007; 19:523–531.

36. Khunnawat C, Mukerji S, Havlichek D Jr, Touma R, Abela GS. Cardiovascular manifestations in human immunodeficiency virus-infected patients. Am J Cardiol. 2008; 102:635–642.

37. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360:1815–1826.

38. Calza L, Manfredi R, Pocaterra D, Chiodo F. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy. J Infect. 2008; 57:16–32.

39. Lakatta EG, Wang M, Najjar SS. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am. 2009; 93:583–604.

40. Schillaci G, De Socio GV, Pirro M, Savarese G, Mannarino MR, Baldelli F, et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol. 2005; 25:2381–2385.

41. Schillaci G, Pucci G, De Socio GV. HIV infection and antiretroviral treatment: a "two-hit" model for arterial stiffness? Am J Hypertens. 2009; 22:817–818.

42. van Leuven SI, Sankatsing RR, Vermeulen JN, Kastelein JJ, Reiss P, Stroes ES. Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart! Curr Opin HIV AIDS. 2007; 2:324–331.

43. Noor MA. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications. Curr HIV/AIDS Rep. 2007; 4:126–134.

44. DAD Study Group. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte AD, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356:1723–1735.

45. De Socio GV, Bonfanti P, Martinelli C, Ricci E, Pucci G, Marinoni M, et al. Negative influence of HIV infection on day-night blood pressure variability. J Acquir Immune Defic Syndr. 2010; 55:356–360.

46. Birkenhäger AM, van den Meiracker AH. Causes and consequences of a non-dipping blood pressure profile. Neth J Med. 2007; 65:127–131.

47. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363:157–163.

48. Snehalatha C, Viswanathan V, Ramachandran A. Cutoff values for normal anthropometric variables in asian Indian adults. Diabetes Care. 2003; 26:1380–1384.

49. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord. 1998; 22:1164–1171.

50. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004; 27:1182–1186.

51. Akosah KO, McHugh VL, Barnhart SI, Mathiason MA, Schaper AM, Perlock PA. Pilot Results of the Early Detection by Ultrasound of Carotid Artery Intima-Media Thickness Evaluation (EDUCATE) study. Am J Hypertens. 2007; 20:1183–1188.

52. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb. 1991; 11:1245–1249.

TOOLS

Similar articles